New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Aligos Therapeutics, Inc. (ALGS) vs Cellectar Biosciences, Inc. (CLRB)
- Aligos Therapeutics, Inc. ALGS 1.22 −2.40%
- Cellectar Biosciences, Inc. CLRB 0.80 −9.09%
Aligos Therapeutics, Inc. and Cellectar Biosciences, Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and Cellectar Biosciences, Inc. are of similar size ($8.9M and $8.8M). Cellectar Biosciences, Inc. has the higher net margin (0.00% vs −197.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Cellectar Biosciences, Inc. leads on 8 and Aligos Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | ALGS | CLRB | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 70.18% |
| Operating margin | (215.55%) | 0.00% | 0.00% |
| Net margin | (197.01%) | 0.00% | 0.00% |
| Free cash flow margin | (204.07%) | 0.00% | 0.00% |
| Return on equity | (159.46%) | (172.99%) | (51.58%) |
| Return on assets | (84.46%) | (116.54%) | (45.91%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack